المؤلفون: L. V. Spirina, A. K. Gorbunov, I. V. Kondakova, E. A. Usynin, E. M. Slonimskaya

المصدر: Успехи молекулярной онкологии, Vol 6, Iss 1, Pp 44-48 (2019)

مصطلحات موضوعية: рак предстательной железы, ar, er, тестостерон, простатический специфический антиген, андрогендепривационная терапия, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

العلاقة: https://umo.abvpress.ru/jour/article/view/205Test; https://doaj.org/toc/2313-805XTest; https://doaj.org/toc/2413-3787Test

الوصول الحر: https://doaj.org/article/0030a05422bb4c478c2379e771ea7c3cTest

المؤلفون: L. V. Spirina, A. К. Gorbunov, I. V. Kondakova, E. М. Slonimskaya, Е. A. Usynin, N. V. Tarasenko

المصدر: Бюллетень сибирской медицины, Vol 17, Iss 3, Pp 122-130 (2018)

مصطلحات موضوعية: рак предстательной железы, транскрипционный фактор trim16, ar, erα, erβ, Medicine

وصف الملف: electronic resource

العلاقة: https://bulletin.ssmu.ru/jour/article/view/1291Test; https://doaj.org/toc/1682-0363Test; https://doaj.org/toc/1819-3684Test

الوصول الحر: https://doaj.org/article/9a30a43c2ca84baab654db737fdf415dTest

المؤلفون: L. V. Spirina, A. K. Gorbunov, I. V. Kondakova, E. M. Slonimskaya, E. A. Usynin

المصدر: Сибирский онкологический журнал, Vol 17, Iss 1, Pp 26-31 (2018)

مصطلحات موضوعية: транскрипционный фактор brn-3α, рак предстательной железы, ar, er, сигнальный путь akt/m-tor, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

العلاقة: https://www.siboncoj.ru/jour/article/view/667Test; https://doaj.org/toc/1814-4861Test; https://doaj.org/toc/2312-3168Test

الوصول الحر: https://doaj.org/article/334aa712e79c401f9e4a000a3fe80c73Test

المؤلفون: L. V. Spirina, E. A. Usynin, E. M. Slonimskaya, I. V. Kondakova, A. K. Gorbunov, Л. В. Спирина, Е. А. Усынин, Е. М. Слонимская, И. В. Кондакова, А. К. Горбунов

المصدر: Siberian journal of oncology; № 4 (2015); 80-86 ; Сибирский онкологический журнал; № 4 (2015); 80-86 ; 2312-3168 ; 1814-4861 ; undefined

مصطلحات موضوعية: рак предстательной железы, нейрегулины, HGF, c-Met, ErbB

وصف الملف: application/pdf

العلاقة: https://www.siboncoj.ru/jour/article/view/227/229Test; Спирина Л.В., Кондакова И.В., Усынин Е.А., Коломиец Л.А., Чойнзонов Е.Л., Мухамедов М.Р., Чернышова А.Л., Шарова Н.П. Активность протеасом в тканях злокачественных опухолей различных локализаций // Сибирский онкологический журнал. 2009. № 5. С. 49–52.; Ancot F., Leroy C., Muharram G., Lefebvre J., Vicogne J., Lemiere A., Kherrouche Z., Foveau B., Pourtier A., Melnyk O., Giordano S., Chotteau-Lelievre A., Tulasne D. Shedding-generated Met receptor fragments can be routed to either the proteasomal or the lysosomal degradation pathway // Traffic. 2012. Vol. 13 (9). P. 1261–1272. doi:10.1111/j.1600-0854.2012.01384.x; Bachleitner-Hofmann T., Sun M.Y., Chen C.T., Tang L., Song L., Zeng Z., Shah M., Christensen J.G., Rosen N., Solit D.B., Weiser M.R. HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells // Mol. Cancer Ther. 2008. Vol. 7 (11). P. 3499–3508. doi:10.1158/1535-7163.MCT-08-0374.; Barnes C.J., Li F., Talukder A.H., Kumar R. Growth factor regulation of a 26S proteasomal subunit in breast cancer // Clin. Cancer Res. 2005. Vol. 11 (8). P. 2868–2874.; Basilico C., Arnesano A., Galluzzo M., Comoglio P.M., Michieli P. A high affinity hepatocyte growth factor-binding site in the immunoglobulinlike region of Met // J. Biol. Chem. 2008. Vol. 283. P. 21267–21277.; Carrion-Salip D., Panosa C., Menendez J.A., Puig T., Oliveras G., Pandiella A., De Llorens R., Massaguer A. Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands // Int. J. Oncol. 2012. Vol. 41 (3). P. 1128–1138. doi:10.3892/ijo.2012.1509.; Chang H., Riese D.J., Gilbert W., Stern D.E., McMahan U.J. Ligands for ErbB-family receptors encoded by a neuregulin-like gene // Nature. 1997. Vol. 387. P. 509–512.; Comoglio P.M., Giordano S., Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience // Nat. Rev. Drug Discov. 2008. Vol. 7. P. 504–516.; Cruz J.J., Ocana A., Del Barco E., Pandiella A. Targeting receptor tyrosine kinases and their signal transduction routes in head and neck cancer // Ann. Oncol. 2007. Vol. 18. P. 421–430.; Garcia-Guzman M., Dolfi F., Zeh K., Vuori K. Met-induced JNK activation is mediated by the adapter protein Crk and correlates with the Gab1 - Crk signaling complex formation // Oncogene. 1999. Vol. 1. P. 7775–7786.; Grimsley S.J., Shini S., Underwood M.A., Edwards J. Heregulin expression and prognosis in prostate adenocarcinoma // Urol. Int. 2011. Vol. 87 (3). P. 363–368. doi:10.1159/000328627.; Groenen L.C., Nice E.C., Burgess A.W. Structure-function relationships for the EGF/TGF-alpha family of mitogens // Growth Factors. 1994. Vol. 11. P. 235–257.; Harari D., Tzahar E., Romano J., Shelly M., Pierce J.H., Andrews G.C., Yarden Y. Neuregulin-4: a novel growth factor that acts through the ErbB-4 receptor tyrosine kinase // Oncogene. 1999. Vol. 18. P. 2681–2689.; Humphrey P.A., Halabi S., Picus J., Sanford B., Vogelzang N.J., Small E.J., Kantoff P.W. Prognostic significance of plasma scatter factor/ hepatocyte growth factor levels in patients with metastatic hormonerefractory prostate cancer: results from cancer and leukemia group B 150005/9480 // Clin. Genitourin. Cancer. 2006. Vol. 4. P. 269–274.; Hynes N.E., Lane H.A. ERBB receptors and cancer: the complexity of targeted inhibitors // Nat. Rev. Cancer. 2005. Vol. 5. P. 341–354.; Jefferd M., Taylir M., Weidner K.M., Omura S., Vande Wiude G.F. Degradation of the Met tyrosine kinase receptor by the ubiquitin-proteasome pathway // Mol. Cell Biol. 1997. Vol. 17 (2). P. 799–808.; Jo M., Stolz D.B., Esplen J.E., Dorko K., Michalopoulos G.K., Strom S.C. Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells // J. Biol. Chem. 2000. Vol. 275. P. 8806–8811.; Kehinde E.O., Maghrebi M.A., Anim J.T. The importance of determining the aggressiveness of prostate cancer using serum and tissue molecular markers // Can. J. Urol. 2008. Vol. 15 (2). P. 3967–3974.; Knudsen B.S., Edlund M. Prostate cancer and the met hepatocyte growth factor receptor // Adv. Cancer Res. 2004. Vol. 91. P. 31–67.; Lai A.Z., Abella J.V., Park M. Crosstalk in Met receptor oncogenesis // Trends Cell Biol. 2009. Vol. 19 (10). P. 542–551. doi:10.1016/j.tcb.2009.07.002.; Lee R.J., Smith M.R. Targeting MET and VEGFR Signaling in Castration-Resistant Prostate Cancer // Cancer J. 2013. Vol. 19 (1). P. 90–98.; Li C., Ma J., Zhao H., Blagg B.S., Dobrowsky R.T. Induction of heat shock protein 70 (Hsp70) prevents neuregulin-induced demyelination by enhancing the proteasomal clearance of c-Jun // ASN Neuro. 2012. Vol. 4 (7). P. 425–437. doi:10.1042/20120047.; Li J.X., Fei X.M., Lu H., Hu H.J., Li J.Y. Effect of proteasome inhibitor on migration ability and hepatocyte growth factor expression of bone marrow mesenchymal stem cells in multiple myeloma patients // Zhongguo Shi Yan Xue Ye Za Zhi. 2011. Vol. 19 (5). P. 1204–1208.; Magnifico A., Tagliabue E., Ardini E., Casalini P., Colnaghi M.I., Menaed S. Heregulin beta1 induces the down regulation and the ubiquitinproteasome degradation pathway of p185HER2 oncoprotein // FEBS Lett. 1998. Vol. 422 (2). P. 129–131.; Montero J.C., Rodriguez-Barrueco R., Ocana A., Diaz-Rodriguez E., Wsparis-Ogando A., Pandiella A. Neuregulins and cancer // Clin. Cancer Res. 2008. Vol. 14 (11). P. 3237–3241.; Naughton M., Picus J., Zhu X., Catalona W.J., Vollmer R.T., Humphrey P.A. Scatter factor-hepatocyte growh factor elevation in the serum of patients with prostate cancer // J. Urol. 2001. Vol. 165. P. 1325–1328.; Paumelle R., Tulasne D., Kherrouche Z., Plaza S., Leroy C., Reveneau S., Vandenbunder B., Fafeur V. Hepatocyte growth factor/scatter factor activates the ETS1 transcription factor by a RAS-RAF-MEK-ERK signaling pathway // Oncogene. 2002. Vol. 21. P. 2309–2319.; Pfeil K., Edel I.E., Putz T., Ramonet R., Culig Z., Ueberall F., Bartsch G., Klocker H. Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells // Prostate. 2004. Vol. 58 (3). P. 259–268.; Pignon J.C., Koopmansch B., Nolens G., Delacroix L., Waltregny D., Winkler R. Androgen receptor controls EGFR and ERBB2 gene expression at different levels in prostate cancer cell lines // Cancer Res. 2009. Vol. 69 (7). P. 2941–2949. doi:10.1158/0008-5472.CAN-08-3760.; Ryan C.J., Rosenthal M., Ng S., Alumkal J., Picus G., Gravis G., Fizazi K., Forget F., Machiels J.P., Srinivas S., Zhu M., Nabg R., Oliner K.S., Jiang Y., Loh E., Dubey S., Gerritsen W.R. Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone // Clin. Cancer Res. 2013. Vol. 19 (1). P. 215–224. doi:10.1158/1078-0432.CCR-12-2605.; Schmukler E., Shai B., Ehrlich M., Pinkas-Kramarski R. Neuregulin promotes incomplete autophagy of prostate cancer cells that is independent of mTOR pathway inhibition // PloS One. 2012. Vol. 7 (5). e36828. doi:10.1371/journal.pone.0036828.; Shimizu H., Seiki T., Asada M., Yoshimatsu K., Koyama N. Alpha6- beta1 integrin induces proteasome-mediated cleavage of erbB2 in breast cancer cells // Oncogene. 2003. Vol. 22 (6). P. 831–839.; Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene // Science. 1987. Vol. 235. P. 177–182.; Syed Z.A., Yin W., Hughes K., Gill J.N., Shi R., Clifford J.L. HGF/c-met/Stat3 signaling during skin tumor cell invasion: indications for a positive feedback loop // BMC Cancer. 2011. Vol. 11. P. 180. doi:10.1186/1471-2407-11-180.; Tinz M., Chtn B., Chqn S.Y., Semenas J., Abrahamson P.A., Diveyi N. Interaction between c-jun and androgen receptor determines the outcome of taxane therapy in castration resistant prostate cancer // Plos One. 2013. Vol. 8 (11). e79573. doi:10.1371/journal.pone.0079573.; Tu W.H., Zhu C., Clark C., Christensen J.C., Sun Z. Efficacy of c-Met inhibitor for advanced prostate cancer // BMC Cancer. 2010. Vol. 10. P. 556. doi:10.1186/1471-2407-10-556.; Wicha M.S. B4 androgen ablation: attacking the prostate cancer stem cell // J. Clin. Invest. 2013. Vol. 123 (2). P. 563–565. doi:10.1172/JCI67460.; Xiao G.H., Jeffers M., Bellacosa A., Mitsuuchi Y., Vande Woude G.F., Testa J.R. Anti-apoptotic signaling by hepatocyte growth factor/ Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways // Proc. Natl. Acad. Sci. USA. 2001. Vol. 98. P. 247–252.; Yeh C.Y., Shin S.M., Yeh H.H., Wu T.J., Shin J.W., Chang T.Y. [et al.]. Transcriptional activation of the Axl and PDGFR-alpha by c-Met through a ras- and Src-independent mechanism in human bladder cancer // BMC Cancer. 2011. Vol. 11. P. 139. doi:10.1186/1471-2407-11-139.; Yonezawa M., Wada K., Tatsuguchi A., Akamatsu A., Gudis K., Seo T., Mitsui K., Nagata K., Tanaka S., Fujimori S., Sakamoto C. Heregulin-induced VEGF expression via the ErbB3 signaling pathway in colon cancer // Digestion. 2009. Vol. 80 (4). P. 215–225. doi:10.1159/000229775.; Yu H., Li X., Sun S., Gao X., Zhou D. c-Met inhibitor SU11274 enhances the response of the prostate cancer cell line DU145 to ionizing radiation // Biochem. Biophys. Res. Commun. 2012. Vol. 427 (3). P. 659–665. doi:10.1016/j.bbrc.2012.09.117.; Zhang D., Sliwkowski M.X., Mark M., Frantz G., Akita R., Sun Y., Jillan K., Crowley C., Brush J., Godowski P.J. Neuregulin-3 (NRG3): a novel neural tissue-enriched protein that binds and activates ErbB4 // PNAS (USA). 1997. Vol. 94 (18). P. 9562–9567.; Zhou H., Zhang Y., Hamburger A.W. EBP1 inhibits translation of androgen receptor mRNA in castration resistant prostate cancer cells // Anticancer Res. 2011. Vol. 31 (10). P. 3129–3135.; https://www.siboncoj.ru/jour/article/view/227Test; undefined

الإتاحة: https://doi.org/10.1111/j.1600-0854.2012.01384.x10.1158/1535-7163.MCT-08-037410.3892/ijo.2012.150910.1159/00032862710.1016/j.tcb.2009.07.00210.1042/2012004710.1158/0008-5472.CAN-08-376010.1158/1078-0432.CCR-12-260510.1371/journal.pone.003682810.1186/1471-2407-11-18010.1371/journal.pone.007957310.1186/1471-2407-10-55610.1172/JCI6746010.1186/1471-2407-11-13910.1159/00022977510.1016/j.bbrc.2012.09.117Test
https://www.siboncoj.ru/jour/article/view/227Test

المؤلفون: L. V. Spirina, E. A. Usynin, E. M. Slonimskaya, I. V. Kondakova, A. K. Gorbunov

المصدر: Сибирский онкологический журнал, Vol 1, Iss 4, Pp 80-86 (2016)

مصطلحات موضوعية: рак предстательной железы, нейрегулины, hgf, c-met, erbb, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

العلاقة: https://www.siboncoj.ru/jour/article/view/227Test; https://doaj.org/toc/1814-4861Test; https://doaj.org/toc/2312-3168Test; https://doaj.org/article/2f640538e50a4434a38327d98ad47368Test

الإتاحة: https://doaj.org/article/2f640538e50a4434a38327d98ad47368Test